{"transactions":[{"id":4639636,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-13T21:12:52.000Z","date":"2026-10-12","kind":"grant","planned":false,"acquired":true,"shares":389,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately."}],"balance_after":19252,"source":{"system":"sec-edgar","filing":"0001193125-26-420641","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1916764/000119312526420641/ownership.xml","form_type":"4"}},{"id":4627150,"issuer":{"id":6392,"kind":"organization","name":"CYPHERPUNK TECHNOLOGIES INC.","symbol":"CYPH"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-25T22:13:25.000Z","date":"2026-09-23","kind":"sale","planned":false,"acquired":false,"shares":50000,"price":3.86,"value":193000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the settlement of restricted stock units."}],"balance_after":118750,"source":{"system":"sec-edgar","filing":"0001104659-26-111061","document":"tm2626176-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1916764/000110465926111061/tm2626176-2_4seq1.xml","form_type":"4"}},{"id":711246,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-10T23:40:14.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":766,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately."}],"balance_after":18863,"source":{"system":"sec-edgar","filing":"0001193125-26-301165","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526301165/ownership.xml","form_type":"4"}},{"id":717343,"issuer":{"id":6392,"kind":"organization","name":"CYPHERPUNK TECHNOLOGIES INC.","symbol":"CYPH"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-07-03T01:56:42.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units (\"RSUs\") to be settled on a 1 for 1 basis for shares of Cypherpunk Technologies Inc. (\"Company\") common stock, par value $0.001 per share (\"Common Stock\"). The RSUs were issued under the Company's 2025 Equity Incentive Plan for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest on June 15, 2027. Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock no later than the fifteenth (15th) day of the third (3rd) calendar month following the calendar year in which the date of grant occurs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest on June 15, 2027. Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock no later than the fifteenth (15th) day of the third (3rd) calendar month following the calendar year in which the date of grant occurs."}],"balance_after":75000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001104659-26-080494","document":"tm2619727-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465926080494/tm2619727-4_4seq1.xml","form_type":"4"}},{"id":810562,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-11T00:51:47.000Z","date":"2026-04-10","kind":"grant","planned":false,"acquired":true,"shares":1192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":18097,"source":{"system":"sec-edgar","filing":"0001193125-26-151626","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526151626/ownership.xml","form_type":"4"}},{"id":830950,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:10:34.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23742,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001193125-26-120223","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120223/ownership.xml","form_type":"4"}},{"id":830949,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:10:34.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":23742,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":23742,"derivative":{"exercise_price":3.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001193125-26-120223","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120223/ownership.xml","form_type":"4"}},{"id":830948,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:10:34.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10362,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":10362},"source":{"system":"sec-edgar","filing":"0001193125-26-120223","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120223/ownership.xml","form_type":"4"}},{"id":830947,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:10:34.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":10362,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":10362,"derivative":{"exercise_price":3.91,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":10362},"source":{"system":"sec-edgar","filing":"0001193125-26-120223","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120223/ownership.xml","form_type":"4"}},{"id":830946,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:10:34.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24999,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.596,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":24999},"source":{"system":"sec-edgar","filing":"0001193125-26-120223","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120223/ownership.xml","form_type":"4"}},{"id":830945,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:10:34.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":24999,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":24999,"derivative":{"exercise_price":3.91,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":24999},"source":{"system":"sec-edgar","filing":"0001193125-26-120223","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120223/ownership.xml","form_type":"4"}},{"id":837106,"issuer":{"id":6392,"kind":"organization","name":"CYPHERPUNK TECHNOLOGIES INC.","symbol":"CYPH"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-03-17T21:58:07.000Z","date":"2026-03-13","kind":"exercise","planned":false,"acquired":false,"shares":94050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the \"December 2025 RSUs\") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The December 2025 RSUs vested at issuance on their grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The December 2025 RSUs vested at issuance on their grant date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":94050},"source":{"system":"sec-edgar","filing":"0001104659-26-029637","document":"tm269084-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465926029637/tm269084-4_4seq1.xml","form_type":"4"}},{"id":837105,"issuer":{"id":6392,"kind":"organization","name":"CYPHERPUNK TECHNOLOGIES INC.","symbol":"CYPH"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-03-17T21:58:07.000Z","date":"2026-03-13","kind":"exercise","planned":false,"acquired":false,"shares":74700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"74,700 Restricted Stock Units (\"RSUs\") previously granted by Cypherpunk Technologies Inc. (the \"Company\") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the \"November 2025 RSUs\") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share (\"Common Stock\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The November 2025 RSUs vested at issuance on their grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The November 2025 RSUs vested at issuance on their grant date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":74700},"source":{"system":"sec-edgar","filing":"0001104659-26-029637","document":"tm269084-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465926029637/tm269084-4_4seq1.xml","form_type":"4"}},{"id":837104,"issuer":{"id":6392,"kind":"organization","name":"CYPHERPUNK TECHNOLOGIES INC.","symbol":"CYPH"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-17T21:58:07.000Z","date":"2026-03-13","kind":"exercise","planned":false,"acquired":true,"shares":94050,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the \"December 2025 RSUs\") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the \"December 2025 RSUs\") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock."}],"balance_after":168750,"source":{"system":"sec-edgar","filing":"0001104659-26-029637","document":"tm269084-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465926029637/tm269084-4_4seq1.xml","form_type":"4"}},{"id":837103,"issuer":{"id":6392,"kind":"organization","name":"CYPHERPUNK TECHNOLOGIES INC.","symbol":"CYPH"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-17T21:58:07.000Z","date":"2026-03-13","kind":"exercise","planned":false,"acquired":true,"shares":74700,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"74,700 Restricted Stock Units (\"RSUs\") previously granted by Cypherpunk Technologies Inc. (the \"Company\") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the \"November 2025 RSUs\") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share (\"Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"74,700 Restricted Stock Units (\"RSUs\") previously granted by Cypherpunk Technologies Inc. (the \"Company\") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the \"November 2025 RSUs\") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share (\"Common Stock\")."}],"balance_after":74700,"source":{"system":"sec-edgar","filing":"0001104659-26-029637","document":"tm269084-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465926029637/tm269084-4_4seq1.xml","form_type":"4"}},{"id":888255,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-23T21:24:13.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date."}],"balance_after":20400,"derivative":{"exercise_price":1.04,"expiration_date":"2036-02-19","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001193125-26-064069","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526064069/ownership.xml","form_type":"4"}},{"id":939306,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T22:06:50.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":3650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":16905,"source":{"system":"sec-edgar","filing":"0001193125-26-013038","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526013038/ownership.xml","form_type":"4"}},{"id":957028,"issuer":{"id":6392,"kind":"organization","name":"CYPHERPUNK TECHNOLOGIES INC.","symbol":"CYPH"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-12-30T21:38:27.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":94050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units (\"RSUs\") to be settled on a 1 for 1 basis for shares of Cypherpunk Technologies Inc. (\"Company\") common stock, par value $0.001 per share (\"Common Stock\"). The RSUs were awarded pursuant to the Company's 2025 Equity Incentive Plan for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested at issuance on December 23, 2025 (the \"Grant Date\"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested at issuance on December 23, 2025 (the \"Grant Date\"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date."}],"balance_after":94050,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":94050},"source":{"system":"sec-edgar","filing":"0001104659-25-125263","document":"tm2534450-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925125263/tm2534450-9_4seq1.xml","form_type":"4"}},{"id":999938,"issuer":{"id":6392,"kind":"organization","name":"CYPHERPUNK TECHNOLOGIES INC.","symbol":"CYPH"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-11-13T21:58:00.000Z","date":"2025-11-11","kind":"grant","planned":false,"acquired":true,"shares":74700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units (\"RSUs\") to be settled on a 1 for 1 basis for shares of Cypherpunk Technologies Inc. (\"Company\") common stock, par value $0.001 per share (\"Common Stock\").  The RSUs were awarded pursuant to the Company's 2022 Equity Incentive Plan for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested at issuance on November 11, 2025 (the \"Grant Date\").  Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested at issuance on November 11, 2025 (the \"Grant Date\").  Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date."}],"balance_after":74700,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":74700},"source":{"system":"sec-edgar","filing":"0001104659-25-111446","document":"tm2531210-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925111446/tm2531210-8_4seq1.xml","form_type":"4"}},{"id":1019387,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-14T20:01:03.000Z","date":"2025-10-10","kind":"grant","planned":false,"acquired":true,"shares":3274,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":13255,"source":{"system":"sec-edgar","filing":"0001193125-25-238982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312525238982/ownership.xml","form_type":"4"}},{"id":1088656,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-11T22:17:36.000Z","date":"2025-07-10","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":9981,"source":{"system":"sec-edgar","filing":"0000950170-25-095403","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025095403/ownership.xml","form_type":"4"}},{"id":1135582,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T21:03:03.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":19111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on March 31, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":19111,"derivative":{"exercise_price":1.19,"expiration_date":"2035-05-21","underlying":"Common Stock","underlying_shares":19111},"source":{"system":"sec-edgar","filing":"0000950170-25-077070","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025077070/ownership.xml","form_type":"4"}},{"id":1173387,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T20:57:47.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":3065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":6231,"source":{"system":"sec-edgar","filing":"0000950170-25-053355","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025053355/ownership.xml","form_type":"4"}},{"id":1323011,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T23:42:57.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":3166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":3166,"source":{"system":"sec-edgar","filing":"0000950170-24-139804","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024139804/ownership.xml","form_type":"4"}},{"id":1390656,"issuer":{"id":6392,"kind":"organization","name":"CYPHERPUNK TECHNOLOGIES INC.","symbol":"CYPH"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T21:25:37.000Z","date":"2024-10-02","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025 and for so long as the reporting person continues to be a director, consultant or service provider of the Company."}],"balance_after":25000,"derivative":{"exercise_price":2.45,"expiration_date":"2034-10-02","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-24-106340","document":"tm2425653-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924106340/tm2425653-7_4seq1.xml","form_type":"4"}},{"id":1472246,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T21:56:38.000Z","date":"2024-06-19","kind":"grant","planned":false,"acquired":true,"shares":64503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the one-year anniversary of June 19, 2024 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date."}],"balance_after":64503,"derivative":{"exercise_price":2,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":64503},"source":{"system":"sec-edgar","filing":"0000950170-24-076369","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024076369/ownership.xml","form_type":"4"}},{"id":1664893,"issuer":{"id":6392,"kind":"organization","name":"CYPHERPUNK TECHNOLOGIES INC.","symbol":"CYPH"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-01T02:34:18.000Z","date":"2024-01-29","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company."}],"balance_after":25000,"derivative":{"exercise_price":2.68,"expiration_date":"2034-01-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-24-009023","document":"tm244775-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924009023/tm244775-12_4seq1.xml","form_type":"4"}},{"id":1796075,"issuer":{"id":6392,"kind":"organization","name":"CYPHERPUNK TECHNOLOGIES INC.","symbol":"CYPH"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-25T20:31:20.000Z","date":"2023-08-23","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of November 23, 2023, February 23, 2024, May 23, 2024 and August 23, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company."}],"balance_after":15000,"derivative":{"exercise_price":2.21,"expiration_date":"2033-08-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-23-095358","document":"tm2324823-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923095358/tm2324823-4_4seq1.xml","form_type":"4"}},{"id":1860915,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option\n(right to buy)","published_at":"2023-06-10T00:42:46.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":23742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date."}],"balance_after":23742,"derivative":{"exercise_price":5.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0000899243-23-015313","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924323015313/doc4.xml","form_type":"4"}},{"id":1927026,"issuer":{"id":6392,"kind":"organization","name":"CYPHERPUNK TECHNOLOGIES INC.","symbol":"CYPH"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-05T00:12:32.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023 for so long as the reporting person continues to be a director, consultant or service provider of the Company until the Option is fully vested."}],"balance_after":150000,"derivative":{"exercise_price":0.34,"expiration_date":"2033-03-31","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001104659-23-041746","document":"tm2311741-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923041746/tm2311741-5_4seq1.xml","form_type":"4"}},{"id":2270603,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31007,"kind":"person","name":"Martin Patricia A.","position":1,"cik":"0001916764","reported_name":"Martin Patricia A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-17T01:22:40.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":10362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as follows: 1/12 of the shares shall vest on each monthly anniversary as measured from March 25, 2022."}],"balance_after":10362,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":10362},"source":{"system":"sec-edgar","filing":"0000899243-22-018290","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322018290/doc4.xml","form_type":"4"}}]}